SCHEMBL1109044

SCHEMBL1109044

COc1ccc(CN(c2ncns2)S(=O)(=O)c2ccc(F)c(C)c2)c(OC)c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 4/20 0.47
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
TP53 P04637 2/20 0.36
TNF P01375 1/20 0.36
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
POLB P06746 1/20 0.35
TAS2R14 Q9NYV8 1/20 0.35
ALDH1A1 P00352 1/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
KDM4E B2RXH2 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
KEAP1 Q14145 1/20 0.34
NFE2L2 Q16236 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16109346 0.93 SCN9A (0.48) SCN9AMEN1KMT2ATP53CNR1
SCHEMBL1095344 0.90 SCN9A (0.46) SCN9AMEN1KMT2ATP53POLB
SCHEMBL325911 0.90 SCN9A (0.46) SCN9AMEN1KMT2ATP53CNR1
SCHEMBL29669273 0.90 SCN9A (0.46) SCN9AMEN1KMT2ATP53POLB
SCHEMBL17048645 0.89 SCN9A (0.49) SCN9AMEN1KMT2ATP53CNR1
SCHEMBL9924609 0.88 SCN9A (0.41) SCN9AMEN1KMT2ATP53POLB
SCHEMBL14921517 0.88 SCN9A (0.45) SCN9AMEN1KMT2ATP53CNR1
SCHEMBL31093304 0.88 SCN9A (0.45) SCN9A
SCHEMBL14699068 0.88 SCN9A (0.46) SCN9AMEN1KMT2APOLBALDH1A1
SCHEMBL319158 0.88 SCN9A (0.45) SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153814-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2012-04-10 US disclosed
US-20100197655-A1 SULFONAMIDE DERIVATIVES Pfizer Limited Icagen, Inc. 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197655-A1 SULFONAMIDE DERIVATIVES SULT2A1, SULT1A1, TPST2 SCN9A 73/4885MEN1 4141/4885KMT2A 3314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.